Merck KGaA, Darmstadt, Germany

FDA approves a third CSF-1R inhibitor for a rare joint tumor

Holder of worldwide commercialization rights to pimicotinib

Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive growth in the joints, tendon sheaths and bursae. For patients whose tumor sits where surgery would damage the joint more than the disease, treatment options have been limited.

Updated 2 hours ago

Merck KGaA to buy Silence Therapeutics for $1.3 billion

Money Moves

Acquirer

Merck KGaA agreed on October 19 to buy Silence Therapeutics for $1.3 billion in cash, paying $20 per American Depositary Share. That is 130% above Silence's closing price on October 16.

Updated Oct 20

Merck KGaA buys Bio-Techne in its biggest deal since 2015

Money Moves

As of June 2026: Acquirer

Merck KGaA of Darmstadt, Germany, agreed to buy Bio-Techne, a Minneapolis company that makes the reagents, proteins, and imaging tools researchers use at the lab bench. The price is $73 a share in cash, about $11.3 billion, a 36% premium over the recent trading average.

Updated Jun 25

Merck KGaA, Darmstadt, Germany

Stories

FDA approves a third CSF-1R inhibitor for a rare joint tumor

Merck KGaA to buy Silence Therapeutics for $1.3 billion

Merck KGaA buys Bio-Techne in its biggest deal since 2015